日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs

铁木皂苷AIII通过抑制CAR-Treg细胞增强CAR-T细胞的效力并预防复发。

Hou, Mingqi; Zhang, Wenjun; Qi, Ziping; Li, Guiming; Mei, Husheng; Qi, Shuang; Jin, Rui; Zhao, Yuedong; Tang, Xiaochen; Xiu, Bing; Chen, Xiaotong; Zhao, Yunshuo; Hu, Chen; Qian, Changlin; Li, Xiuchun; Xu, Zhan; Chen, Yongfei; Wu, Chao; Wang, Beilei; Yan, Lejin; Li, Dan; Huang, Yushan; Liang, Rui; Wang, Aoli; Liu, Jing; Wang, Wenchao; Li, Bin; Long, Jun; Li, Ping; Liang, Aibin; Liu, Qingsong; Yang, Jing

The predictive value of interleukin-2 receptor and prognostic nutritional index in patients with diffuse large B-cell lymphoma

白细胞介素-2受体和预后营养指数对弥漫性大B细胞淋巴瘤患者的预测价值

Xie, Fengyang; Li, Yulan; Zhu, Xinyu; Zhu, Jingjing; Ma, Xiaoxia; Yan, Dimei; Liang, Aibin; Xiu, Bing

Indolent T-cell lymphoma of the gastrointestinal tract coexisting with gastric signet-ring cell carcinoma: A case report and review of literature

胃肠道惰性T细胞淋巴瘤合并胃印戒细胞癌:病例报告及文献复习

Chen, Xue; Bo, Jia-Qi; Gao, Xiao-Xiang; Zhang, Su-Xia; Li, Jie; Wang, Hui; Yang, Mu-Ye; Guo, Qian-Qian; Xiu, Bing; Zeng, Yu

Ubiquitin-specific protease 7-mediated stabilization of discoidin domain receptor 1 drives progression of TP53-Mutant cancers.

泛素特异性蛋白酶 7 介导的盘状结构域受体 1 的稳定作用驱动 TP53 突变癌症的进展

Xue Yiying, Xiu Bing, Yang Muye, Zhang Yanwei, Yang Changpeng, Zhang Lele, Yan Yilv, Luo Xiu, Huang Yushan, Mei Husheng, Li Guiming, Zhou Lixin, Chen Yisa, Zhang Wenjun, Qian Changlin, Zhang Peng, Liu Juan, Liang Aibin, Zeng Yu, Yang Jing

Single nucleotide polymorphism and promoter methylation analysis of protein tyrosine phosphatase 1B in patients with myeloproliferative neoplasms

骨髓增生性肿瘤患者蛋白酪氨酸磷酸酶1B的单核苷酸多态性和启动子甲基化分析

Zhou, Jie; Wu, Hao; Li, Bing; Zhou, Lili; Zhang, Wenjun; Ding, Yi; Zhu, Xinyu; Lu, Huina; Xiu, Bing; Liang, Aibin; Fu, Jianfei

Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors

病例报告:循环肿瘤DNA技术显示,在BTK抑制剂治疗期间,华氏巨球蛋白血症患者存在时间和空间异质性

Zhu, Jingjing; Zhu, Xinyu; Xie, Fengyang; Ding, Yi; Lu, Huina; Dong, Yan; Li, Ping; Fu, Jianfei; Liang, Aibin; Zeng, Yu; Xiu, Bing

Effect of arsenic trioxide plus etoposide, solumedrol, high‑dose cytarabine and cisplatin chemotherapy on the treatment of relapsed or ref7ractory ALK+ anaplastic large cell lymphoma

三氧化二砷联合依托泊苷、甲泼尼龙、大剂量阿糖胞苷和顺铂化疗对复发或难治性ALK阳性间变性大细胞淋巴瘤的疗效

Ding, Yi; Lu, Huina; Dong, Yan; Xiu, Bing; Liang, Aibin; Zhang, Wenjun

MicroRNA-181b-5p insufficiency predicts treatment response failure risk and unfavorable event-free survival as well as overall survival in acute myeloid leukemia patients

在急性髓系白血病患者中,microRNA-181b-5p 不足可预测治疗反应失败风险、不良的无事件生存期以及总生存期。

Lu, Huina; Ding, Yi; Dong, Yan; Luo, Xiu; Wang, Xiuqin; Xiu, Bing; Liang, Aibin; Zhang, Wenjun

JPHYD Inhibits miR-21-5p/Smad7-Mediated Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells

JPHYD抑制miR-21-5p/Smad7介导的肝细胞癌细胞上皮-间质转化

Li-Hua Liu #, Chong-Kai Fang #, Fu-Cheng Ge #, Ji-Nan Wang #, Xiu-Bing Zhang, Rui Luo, Ying Zhang, Kun-Liang Feng, Zhen-Wen Qiu, Chong Zhong

5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients

cfDNA中5-羟甲基胞嘧啶谱对弥漫性大B细胞淋巴瘤患者的R-CHOP治疗反应具有很高的预测价值。

Chen, Hang-Yu; Zhang, Wei-Long; Zhang, Lei; Yang, Ping; Li, Fang; Yang, Ze-Ruo; Wang, Jing; Pang, Meng; Hong, Yun; Yan, Changjian; Li, Wei; Liu, Jia; Xu, Nuo; Chen, Long; Xiao, Xiu-Bing; Qin, Yan; He, Xiao-Hui; Liu, Hui; Zhu, Hai-Chuan; He, Chuan; Lin, Jian; Jing, Hong-Mei